Device makers, like pharmaceutical manufacturers, have long recognized that their success depends upon making their products known to physicians who will prescribe or recommend the use of their particular product.
In addition to their ability to influence current product use, physicians also are in the best position to conduct or oversee research that may expand future market share, including identifying additional clinical uses or adaptations for a product — some of which may not yet be approved by the U.S. Food and Drug Administration (FDA).
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc. This appeared in both Health Law360 and Competition Law360.
Author(s)
Related Insights
24 January 2025
Foley Viewpoints
Incoming Environmental Protection Agency (EPA) Personnel and Impact on Enforcement
To nobody’s surprise, it is already evident that President Trump’s second term will mark a significant shift in environmental regulation and policy from the Biden Administration.
24 February 2025
Events
Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking in the Health Care Compliance Board & Compliance Committee Conference in the panel “Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General.”
24 January 2025
Foley Viewpoints
Corporate Transparency Act Enforcement Remains Paused
On January 23, 2025, the U.S. Supreme Court issued a stay of the nationwide preliminary injunction issued by a federal district court in Texas in December 2024 in the Texas Top Cop Shop litigation.